Loading
NASDAQHealthcareBiotechnology
Latest quote
$15.14
+$0.11 · +0.73%
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.
Previous close
$15.14
+$0.11 · +0.73%
Regular session · ET · Market data may be delayed.
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.
Day range
Current $15.14
52-week range
Current $15.14
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
40
Expensive
Sentiment
59
Mixed
Risk
52
Elevated Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.
Day range
Current $15.14
52-week range
Current $15.14
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 622K USD | 596K USD | 537K USD | 466K USD | — |
| Gross profit | −622K USD | −596K USD | −537K USD | −466K USD | — |
| Research and development | 59.13M USD | 44.35M USD | 57.06M USD | 48.61M USD | 24.78M USD |
| Selling, general, and administrative | 20.34M USD | 18.03M USD | 21.13M USD | 18.98M USD | 11.05M USD |
| Operating expenses | 78.85M USD | 61.79M USD | 77.65M USD | 67.13M USD | 35.83M USD |
| Interest income | 9.68M USD | 12.8M USD | — | — | — |
| Depreciation and amortization | 622K USD | 596K USD | 537K USD | 466K USD | 129K USD |
| Operating income | −79.47M USD | −62.38M USD | −78.19M USD | −67.59M USD | −35.83M USD |
| Net income | −69.79M USD | −49.59M USD | −66.86M USD | −63.31M USD | −35.53M USD |
Company facts updated Sep 5, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$20.50
35.40% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI14.14M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM12.17M0.02%79.88B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF4.56M0.00%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Growth ETFIWO4.35M0.03%14.58B USD0.24%$377.54+0.12%
iShares Biotechnology ETFIBB4.22M0.04%10.72B USD0.44%$211.92-0.88%
Fidelity Enhanced Small Cap ETFFESM3.55M0.05%6.03B USD0.28%$47.36+0.21%
Dimensional - US Small Cap ETFDFAS2.35M0.02%15.54B USD0.26%$82.20+0.18%
Schwab U.S. Small-Cap ETFSCHA2.34M0.01%22.56B USD0.03%$34.55+1.01%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBFidelity Enhanced Small Cap ETFFESMDimensional - US Small Cap ETFDFASSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
